<?xml version="1.0" encoding="UTF-8"?>
<p id="para1850">There has been no well done community study of HCV prevalence, but estimates from the Ministry of Health for 2016 approximate that it is 0·1%.
 <xref rid="bib96" ref-type="bibr">
  <sup>96</sup>
 </xref> A study found that HCV seroprevalence was 0·06% in 161 658 blood donors between 2011 and 2014, and in 1575 patients receiving haemodialysis, the prevalence was 2·2%.
 <xref rid="bib97" ref-type="bibr">
  <sup>97</sup>
 </xref> There are no data on risk factors associated with HCV, but a study from a single institution of 266 patients with HCV found that 36% had a history of blood transfusion, 16·6% had a history of intravenous drug use, 12·3% had blood disorders, and 8·8% were receiving haemodialysis.
 <xref rid="bib98" ref-type="bibr">
  <sup>98</sup>
 </xref> Nucleic acid amplification testing is effectively used to screen blood products in Singapore. The country has does not have formal harm reduction strategies because its official stance on drug use is zero tolerance.
</p>
